The current landscape for treating Covid-19 reveals a limited arsenal, with remdesivir and dexamethasone being the primary options, yet neither significantly reduces mortality. A new contender, CD 24 FC, has emerged, prompting a strategic partnership with a major pharmaceutical player to accelerate its development. Personal connections and strategic decisions play a crucial role in navigating the complexities of bringing life-saving drugs to market during a pandemic.
